Review Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma

<p><a name="_msoanchor_1" href="file:///R:/PROJECTS/2019%20Projects/Celgene/5.%20Marketing/1.%20RMD%20Brief/Copy%20Doc/ECK%20043021%20Marketing%20Collateral%20Copy%20Request_BMS%20Audio%20Brief_EC-SN.docx#_msocom_1"></a></p> <p>Have you considered POMALYST<span>^®</span><span>(pomalidomide) </span>containing regimens for your appropriate patients with relapsed/refractory multiple myeloma <span>who have received lenalidomide and a proteasome inhibitor?</span> Tune in to hear key findings from clinical trials, including safety and efficacy data, and other important information regarding these treatment regimens.</p> <p><strong>Please see full Prescribing Information for <a href="https://packageinserts.bms.com/pi/pi_pomalyst.pdf"><span style="text-decoration: underline;">POMALYST</span></a>, including Boxed WARNINGS, and full Prescribing Information for <a href="https://packageinserts.bms.com/pi/pi_empliciti.pdf"><span style="text-decoration: underline;">EMPLICITI</span></a>.</strong></p> <p><strong><span style="color: teal;">POMALYST and EMPLICITI Indications</span></strong></p> <p>POMALYST^® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.</p> <p>EMPLICITI^® (elotuzumab) is indicated in combination with POMALYST and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.</p> <p><strong>POMALYST + dexamethasone + daratumumab Indication</strong></p> <p>POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.</p> <p><strong>Information about POMALYST